Quickstart Highlights
The AOD-9604 6mg + CJC-1295 3mg + Ipamorelin 3mg (12mg Blend Vial) dosage protocol is designed for research purposes to explore potential metabolic, regenerative, and fat oxidation effects via daily subcutaneous injections.
- Typical starting dose: 400 mcg daily, with gradual titration up to 1.2 mg daily
- Single daily injection ensures ease of use and accurate dosing
- Titration phases allow for safe adjustment based on research parameters
- Reconstitute with 3 mL bacteriostatic water to achieve a 4 mg/mL solution
- Store lyophilized vials in the freezer; reconstituted solution must be refrigerated
Important: Before viewing any protocol, please consult our Prep & Injection Guide for essential preparation and safety instructions.Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (Reconstituted with 3 mL = 4 mg/mL)
| Phase | Daily Dose | Approx. Units (per injection) |
|---|---|---|
| Weeks 1–4 | 400 mcg (0.4 mg) | 10 units |
| Weeks 5–8 | 800 mcg (0.8 mg) | 20 units |
| Weeks 9–12 | 1,200 mcg (1.2 mg) | 30 units |
Reconstitute the vial with 3 mL of bacteriostatic water to create a 4 mg/mL solution. If the calculated injection volume falls below 10 units, consider using a smaller insulin syringe for improved dosing accuracy.
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Note: This guide is for research purposes only. Always consult with a qualified professional before use.
Supplies Needed
Ensure you have these on hand for an 8–16 week cycle.
- Peptide Vials:
• 8 wks ≈ 1 vial
• 12 wks ≈ 2 vials
• 16 wks ≈ 3 vials
(More if planning higher doses) - Insulin Syringes:
• 8 wks ≈ 8
• 12 wks ≈ 12
• 16 wks ≈ 16 - Bacteriostatic Water: 1× 30 mL
- Alcohol Swabs: 1 box
Protocol Overview
The AOD-9604 6mg + CJC-1295 3mg + Ipamorelin 3mg (12mg Blend Vial) protocol combines a lipolytic peptide fragment with two growth hormone secretagogues to potentially enhance metabolic regulation and tissue repair. This research-focused regimen uses daily subcutaneous injections with a gradual dose escalation over a 12-week cycle.
- Goal: Investigate metabolic support, fat oxidation, and regenerative properties.
- Schedule: Daily subcutaneous injections over a 12-week cycle.
- Dose Range: Start at 400 mcg daily, increasing to 1.2 mg daily.
- Reconstitution: Reconstitute with 3 mL to achieve a 4 mg/mL solution.
- Storage: Freeze lyophilized vials; refrigerate reconstituted solution at 2–8°C.
Dosing Protocol
This protocol involves a single daily injection with gradual titration:
- Daily Dose: Begin with 400 mcg (10 units) and increase to 1,200 mcg (30 units) as tolerated.
- Injection Frequency: Once daily, preferably at the same time each day.
- Cycle Length: 12 weeks (adjustable based on research parameters).
- Note: Ensure consistent dosing intervals and accurate measurement using a 100-unit insulin syringe.
Storage Instructions
Proper storage ensures peptide integrity.
- Lyophilized: Store in the freezer (−20°C) until reconstitution.
- Reconstituted: Keep in the refrigerator at 2–8°C.
- Use within 30 days of reconstitution; avoid repeated freeze-thaw cycles.
Important Notes
Practical tips to enhance safety and efficacy.
- Always use new, sterile insulin syringes & rotate injection sites.
- Maintain consistent injection times for optimal results.
- Monitor for any adverse reactions and consult with a professional if concerns arise.
- Ensure accurate dosing; if injections are below ~10 units, consider using a smaller insulin syringe.
How This Works
This peptide blend combines:
- AOD-9604: A fragment of human growth hormone, studied for its lipolytic (fat-burning) properties.
- CJC-1295: A growth hormone-releasing hormone analog that may stimulate endogenous GH release.
- Ipamorelin: A selective GH secretagogue that works synergistically with CJC-1295 to potentially enhance tissue repair.
Potential Benefits & Side Effects
Research indicates potential for enhanced metabolic support and tissue repair. Observed benefits and side effects vary based on individual response.
- May support metabolic regulation and fat oxidation.
- Could potentially aid in tissue repair and recovery.
- Common mild side effects: localized injection site irritation, minor redness or discomfort.
- Rarely, systemic effects such as headache or transient dizziness have been reported.
Injection Technique
General subcutaneous guidance from clinical best-practice resources.
- Clean the vial stopper and skin with alcohol; allow to dry[5].
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[5][6].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[7].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[5][6].
- Do not rub the injection site; apply light pressure with gauze if needed.
Lifestyle Factors
For best results, complement this protocol with supportive lifestyle practices.
- Adopt a balanced, nutrient-rich diet with adequate protein.
- Incorporate regular exercise and proper recovery routines.
- Maintain consistent hydration and stress management practices.
Recommended Source
We recommend Pure Lab Peptides for high-purity 5-Amino-1MQ (10 mg).
Why Pure Lab Peptides?
- Start: 150 mcg daily for 2 weeks to assess tolerance.
- Mid-Phase: Increase to 300 mcg daily for weeks 3–4.
- Target: 600 mcg daily by weeks 5–8.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8 weeks minimum; may extend based on research goals.
- Timing: Any consistent time; rotate injection sites.
Important Note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. All current data come from preclinical research in cells and animal models; no human clinical trials have been published to date.
References
Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice
— Sci Rep (2024)
Parenteral Administration: Intradermal, Subcutaneous, and Intramuscular Routes
— Lippincott Williams & Wilkins (2016)
Peptide Storage and Handling Guide: Stability of Reconstituted Peptides
— Creative Peptides Resource (2023)
References
-
Journal of Endocrinology & Metabolism (2014)
— Safety and metabolism of AOD9604: novel nutraceutical ingredient for improved metabolic health -
Journal of Clinical Endocrinology & Metabolism (PubMed)
— Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults -
European Journal of Endocrinology (PubMed)
— Ipamorelin: the first selective growth hormone secretagogue -
Translational Andrology and Urology (PMC)
— Role of growth hormone secretagogues in body composition management -
Endocrinology (OUP)
— hGH and AOD-9604: lipid metabolism and beta-adrenergic pathway insights -
CDC
— Preventing unsafe injection practices: multi-dose vial handling guidelines -
Journal of Endocrinology & Metabolism (2013)
— Safety and tolerability of the hexadecapeptide AOD9604 in humans -
Obesity Pharmacotherapy Review (PMC)
— AOD-9604 clinical trial overview and weight loss outcomes -
Subcutaneous Drug Injection Review (PMC)
— Pharmacologic considerations of the subcutaneous route -
CDC
— Vaccine administration: subcutaneous route (angle/site guidance) -
MedlinePlus
— Subcutaneous injections: patient instructions and technique -
NCBI Bookshelf
— Best practices for injection: asepsis, preparation, and administration -
Central & Peripheral Anti-Obesity Targets (PMC)
— AOD-9604 RCT summary and mechanistic overview -
PubMed
— Metabolic studies of AOD-9604 in obese rodents (oral dosing, fat oxidation) -
Pure Lab Peptides
— AOD-9604 + CJC-1295 + Ipamorelin Blend product page (quality and batch documentation)